Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Scancell Holdings PLC (GB:SCLP)
LSE:SCLP
Holding GB:SCLP?
Track your performance easily
SCLP Stock Chart & Stats
Day’s Range― - ―
52-Week Range8.60p - 19.75p
Previous CloseN/A
Volume797.06K
Average Volume (3M)1.23M
Market Cap
£100.57M
Enterprise Value85.26M
Total Cash (Recent Filing)$2.67M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.38
Next Earnings
Jan 30, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,036,781,400
10 Day Avg. Volume1,679,439
30 Day Avg. Volume1,228,344
Standard Deviation0.25
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)19.08
Price to Cash Flow (P/CF)-7.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit17.96
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Scancell Holdings News
PremiumCompany Announcements
Scancell Holdings Reports Strong Progress in Cancer Vaccine Trials
PremiumCompany Announcements
Scancell Holdings to Announce Interim Results for 2024
PremiumCompany Announcements
Scancell’s Modi-1 Vaccine Shows Promising Early Results in Cancer Treatment
PremiumCompany Announcements
Scancell Holdings Secures £11.3 Million in Oversubscribed Offering
PremiumCompany Announcements
Scancell Holdings Secures £10.3 Million in Oversubscribed Funding
PremiumCompany Announcements
Scancell Holdings to Launch £9 Million Capital Raise
PremiumCompany Announcements
Scancell Holdings Announces Major Capital Raising Initiative
PremiumCompany Announcements
Scancell Holdings and Genmab Strengthen Partnership with New LicenseOptions Prices
Currently, No data available
---
Ownership Overview
SCLP FAQ
What was Scancell Holdings PLC’s price range in the past 12 months?
Scancell Holdings PLC lowest share price was 8.60p and its highest was 19.75p in the past 12 months.
What is Scancell Holdings PLC’s market cap?
Scancell Holdings PLC’s market cap is £100.57M.
When is Scancell Holdings PLC’s upcoming earnings report date?
Scancell Holdings PLC’s upcoming earnings report date is Jan 30, 2025 which is yesterday.
How were Scancell Holdings PLC’s earnings last quarter?
Scancell Holdings PLC released its earnings results on Sep 24, 2024. The company reported -0.004p earnings per share for the quarter, missing the consensus estimate of N/A by -0.004p.
Is Scancell Holdings PLC overvalued?
According to Wall Street analysts Scancell Holdings PLC’s price is currently Overvalued.
Does Scancell Holdings PLC pay dividends?
Scancell Holdings PLC does not currently pay dividends.
What is Scancell Holdings PLC’s EPS estimate?
Scancell Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scancell Holdings PLC have?
Scancell Holdings PLC has 1,036,781,400 shares outstanding.
What happened to Scancell Holdings PLC’s price movement after its last earnings report?
Scancell Holdings PLC reported an EPS of -0.004p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Scancell Holdings PLC?
Currently, no hedge funds are holding shares in GB:SCLP
---
Scancell Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth £1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-22.11%
Trailing 12-Months
Company Description
Scancell Holdings PLC
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.
---
Technical Analysis
AstraZeneca
―
GlaxoSmithKline
―
HUTCHMED (China) Limited
―
ImmuPharma
―
Oxford BioMedica
―
---